Posted On: 01/04/2015 8:47:12 AM
Post# of 30038
"The exosome-based technology used in the study will be further developed by NanoSomiX, a California-based biotechnology company that develops blood assays for neurodegenerative diseases and that is supporting the research.
Dr Kapogiannis emphasized that a blood test for AD is not around the corner .
" The emphasis should be on down the road because these are findings from case-control studies in a small number of patients and the findings need to be replicated and validated in larger studies, but still the findings are very clear cut and reached very high levels of statistical significance," he said.
Simon Lovestone, PhD, from King's College London and the Institute of Psychiatry, United Kingdom, who is not involved in the research, said it's "interesting for two reasons: the link to insulin signaling and the use of exosomes. There are plenty of other studies to make one think both these elements are real and worth pursuing in AD. Combining both makes this a potentially exciting study."
Asked for comment on these findings, Dean M. Hartley, PhD, director of science initiatives at the Alzheimer's Association, told Medscape Medical News that the search for preclinical biomarkers of AD to facilitate early diagnosis is a "very active" area of research.
"A simple blood test that is performed in a doctor's office is certainly something we see as a direction of the future, but this is very much still in the research phase, " he said."
http://www.medscape.com/viewarticle/835489
Dr Kapogiannis emphasized that a blood test for AD is not around the corner .
" The emphasis should be on down the road because these are findings from case-control studies in a small number of patients and the findings need to be replicated and validated in larger studies, but still the findings are very clear cut and reached very high levels of statistical significance," he said.
Simon Lovestone, PhD, from King's College London and the Institute of Psychiatry, United Kingdom, who is not involved in the research, said it's "interesting for two reasons: the link to insulin signaling and the use of exosomes. There are plenty of other studies to make one think both these elements are real and worth pursuing in AD. Combining both makes this a potentially exciting study."
Asked for comment on these findings, Dean M. Hartley, PhD, director of science initiatives at the Alzheimer's Association, told Medscape Medical News that the search for preclinical biomarkers of AD to facilitate early diagnosis is a "very active" area of research.
"A simple blood test that is performed in a doctor's office is certainly something we see as a direction of the future, but this is very much still in the research phase, " he said."
http://www.medscape.com/viewarticle/835489
(0)
(0)Scroll down for more posts ▼
